Essential Hypertension Clinical Trial
Official title:
Effects of Intensive Vasodilating add-on Therapy on Peripheral Vascular Resistance and Coronary Flow Reserve in Patients With Essential Hypertension
The purpose of this study is to determine whether add-on of intensive vasodilator therapy can improve the coronary perfusion and reduce the total peripheral resistance in patients with ongoing treatment for essential hypertension.
Morphological changes are observed in the microvasculature of patients with essential
hypertension. The lumen diameter is reduced in resistance arteries, but with no change in
vessel cross-sectional area or wall mass. These structural changes are termed inward
eutrophic remodelling and results in an increased wall:lumen ratio, caused by rearrangement
of cell matrix and not by hypertrophy of smooth muscle cells in the vascular wall as
observed in secondary forms of hypertension. The morphological changes also occur in the
coronary arteries and cause a reduction in the ability to increase coronary perfusion as
response to increased cardiac work. This is observed as a reduced coronary flow reserve in
patients with sustained hypertension.
Two recently published clinical studies associates an increase in media:lumen ratio with an
increased risk of cardiovascular events, and it therefore seems beneficial to normalize the
vascular structure in patients with essential hypertension. It has previously been
demonstrated that reversion of vascular remodelling and thereby normalization of the
vascular structure, requires vasodilatation and not just blood pressure reduction,
suggesting that patients with essential hypertension can benefit from antihypertensive
treatment aimed to induce vasodilatation.
The purpose of this study is to determine whether add-on of intensive vasodilator therapy
can improve the coronary perfusion (coronary flow reserve) and reduce the total peripheral
resistance in patients with ongoing treatment for essential hypertension. We also aim to
investigate whether changes in coronary flow reserve correlates better to changes in total
peripheral resistance than changes in blood pressure. Particularly we aim to study if
patients with high total peripheral resistance, despite blood pressure control, can benefit
from intensive vasodilating therapy.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03708601 -
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
|
||
Not yet recruiting |
NCT05503953 -
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
|
Phase 3 | |
Recruiting |
NCT05526703 -
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
|
Phase 3 | |
Completed |
NCT06395194 -
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT06418074 -
Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity
|
N/A | |
Completed |
NCT02890173 -
Study of CS-3150 in Patients With Essential Hypertension
|
Phase 3 | |
Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
Completed |
NCT02944734 -
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT01956786 -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
|
Phase 2/Phase 3 | |
Completed |
NCT02553512 -
Helius in Hypertension-I: The UK Hypertension Registry
|
N/A | |
Completed |
NCT01198249 -
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
|
Phase 1 | |
Completed |
NCT01001572 -
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Recruiting |
NCT00380289 -
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
|
N/A | |
Completed |
NCT00139698 -
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Completed |
NCT00288184 -
Uric Acid in Essential Hypertension in Children
|
Phase 2 | |
Completed |
NCT01289886 -
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06041529 -
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
|
Phase 4 | |
Completed |
NCT04470830 -
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
|
||
Completed |
NCT00758524 -
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT05109013 -
Juvenile Essential Arterial Hypertension and Vascular Function
|